Oblimersen Na | CAS# 190977-41-4 | tumour regressions

MedKoo Cat#: 414533 | Name: Oblimersen Na

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oblimersen Na targets the Bcl-2 oncogene good efficacy with low toxicity tumour regressions

Chemical Structure

Oblimersen Na

CAS#190977-41-4

Theoretical Analysis

MedKoo Cat#: 414533

Name: Oblimersen Na

CAS#: 190977-41-4

Chemical Formula: C172H204N62Na17O91P17S17

Exact Mass: 6054.2294

Molecular Weight: 6058.27

Elemental Analysis: C, 34.10; H, 3.39; N, 14.33; Na, 6.45; O, 24.03; P, 8.69; S, 9.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Oblimersen sodium; Oblimersen Na; G3139; G-3139; G 3139

IUPAC/Chemical Name

P-Thiothymidylyl-(3'to 5')-2'-deoxy-P-thiocytidylyl-(3'to 5')-P-thiothymidylyl-(3'to 5')-2'-deoxy-P-thiocytidylyl-(3'to 5')-2'-deoxy-P-thiocytidylyl-(3'to 5')-2'-deoxy-P-thiocytidylyl-(3'to 5')-2'-deoxy-P-thioadenylyl-(3'to 5')-2'-deoxy-P-thioguanylyl-(3'to 5')-2'-deoxy-P-thiocytidylyl-(3'to 5')-2'-deoxy-P-thioguanylyl-(3'to 5')-P-thiothymidylyl-(3'to 5')-2'-deoxy-P-thioguanylyl-(3'to 5')-2'-deoxy-P-thiocytidylyl-(3'to 5')-2'-deoxy-P-thioguanylyl-(3'to 5')-2'-deoxy-P-thiocytidylyl-(3'to 5')-2'-deoxy-P-thiocytidylyl-(3'to 5')-2'-deoxy-P-thioadenylyl-(3'to 5')-thymidine heptadecasodium salt

InChi Key

IBXPAFBDJCXCDW-MHFPCNPESA-A

InChi Code

InChI=1S/C172H221N62O91P17S17.17Na/c1-69-39-225(169(253)213-149(69)237)117-21-73(236)92(292-117)44-274-326(257,343)320-85-33-129(229-63-191-135-141(181)187-61-189-143(135)229)303-103(85)55-285-332(263,349)314-79-27-122(221-17-9-113(177)201-165(221)249)295-95(79)47-278-330(261,347)312-78-26-121(220-16-8-112(176)200-164(220)248)298-98(78)50-280-338(269,355)322-87-35-131(231-65-193-137-145(231)205-157(183)209-153(137)241)305-105(87)57-287-334(265,351)316-81-29-124(223-19-11-115(179)203-167(223)251)299-99(81)51-281-339(270,356)323-88-36-132(232-66-194-138-146(232)206-158(184)210-154(138)242)307-107(88)59-289-337(268,354)319-84-32-128(228-42-72(4)152(240)216-172(228)256)302-102(84)54-284-341(272,358)325-90-38-134(234-68-196-140-148(234)208-160(186)212-156(140)244)306-106(90)58-288-335(266,352)317-82-30-125(224-20-12-116(180)204-168(224)252)300-100(82)52-282-340(271,357)324-89-37-133(233-67-195-139-147(233)207-159(185)211-155(139)243)308-108(89)60-290-342(273,359)321-86-34-130(230-64-192-136-142(182)188-62-190-144(136)230)304-104(86)56-286-333(264,350)315-80-28-123(222-18-10-114(178)202-166(222)250)296-96(80)48-277-328(259,345)310-76-24-119(218-14-6-110(174)198-162(218)246)294-94(76)46-276-329(260,346)311-77-25-120(219-15-7-111(175)199-163(219)247)297-97(77)49-279-336(267,353)318-83-31-127(227-41-71(3)151(239)215-171(227)255)301-101(83)53-283-331(262,348)313-75-23-118(217-13-5-109(173)197-161(217)245)293-93(75)45-275-327(258,344)309-74-22-126(291-91(74)43-235)226-40-70(2)150(238)214-170(226)254;;;;;;;;;;;;;;;;;/h5-20,39-42,61-68,73-108,117-134,235-236H,21-38,43-60H2,1-4H3,(H,257,343)(H,258,344)(H,259,345)(H,260,346)(H,261,347)(H,262,348)(H,263,349)(H,264,350)(H,265,351)(H,266,352)(H,267,353)(H,268,354)(H,269,355)(H,270,356)(H,271,357)(H,272,358)(H,273,359)(H2,173,197,245)(H2,174,198,246)(H2,175,199,247)(H2,176,200,248)(H2,177,201,249)(H2,178,202,250)(H2,179,203,251)(H2,180,204,252)(H2,181,187,189)(H2,182,188,190)(H,213,237,253)(H,214,238,254)(H,215,239,255)(H,216,240,256)(H3,183,205,209,241)(H3,184,206,210,242)(H3,185,207,211,243)(H3,186,208,212,244);;;;;;;;;;;;;;;;;/q;17*+1/p-17/t73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,326?,327?,328?,329?,330?,331?,332?,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?;;;;;;;;;;;;;;;;;/m0................./s1

SMILES Code

CC1=CN(C(NC1=O)=O)[C@H]2C[C@@H]([C@H](O2)COP([S-])(O[C@H]3C[C@H](n(cn4)c5c4c(N)ncn5)O[C@@H]3COP([S-])(O[C@H]6C[C@H](N7C=CC(N)=NC7=O)O[C@@H]6COP([S-])(O[C@H]8C[C@H](N9C=CC(N)=NC9=O)O[C@@H]8COP([S-])(O[C@H]%10C[C@H](n%11c%12c(C(NC(N)=N%12)=O)nc%11)O[C@@H]%10COP([S-])(O[C@H]%13C[C@H](N%14C=CC(N)=NC%14=O)O[C@@H]%13COP([S-])(O[C@H]%15C[C@H](n%16c%17c(C(NC(N)=N%17)=O)nc%16)O[C@@H]%15COP([S-])(O[C@H]%18C[C@H](N%19C=C(C(NC%19=O)=O)C)O[C@@H]%18COP([S-])(O[C@H]%20C[C@H](n%21c%22c(C(NC(N)=N%22)=O)nc%21)O[C@@H]%20COP([S-])(O[C@H]%23C[C@H](N%24C=CC(N)=NC%24=O)O[C@@H]%23COP([S-])(O[C@H]%25C[C@H](n%26c%27c(C(NC(N)=N%27)=O)nc%26)O[C@@H]%25COP([S-])(O[C@H]%28C[C@H](n(cn%29)c%30c%29c(N)ncn%30)O[C@@H]%28COP([S-])(O[C@H]%31C[C@H](N%32C=CC(N)=NC%32=O)O[C@@H]%31COP([S-])(O[C@H]%33C[C@H](N%34C=CC(N)=NC%34=O)O[C@@H]%33COP([S-])(O[C@H]%35C[C@H](N%36C=CC(N)=NC%36=O)O[C@@H]%35COP([S-])(O[C@H]%37C[C@H](N%38C=C(C(NC%38=O)=O)C)O[C@@H]%37COP([S-])(O[C@H]%39C[C@H](N%40C=CC(N)=NC%40=O)O[C@@H]%39COP([S-])(O[C@H]%41C[C@H](N%42C=C(C(NC%42=O)=O)C)O[C@@H]%41CO)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 6,058.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4245s-4248s. doi: 10.1158/1078-0432.CCR-040018. PMID: 15217967. 2: Frankel SR. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol. 2003 Apr;30(2):300-4. doi: 10.1053/sonc.2003.50041. PMID: 12720157. 3: Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):765-74. doi: 10.1517/17425255.2011.579105. Epub 2011 Apr 27. PMID: 21521129. 4: Moreira JN, Santos A, Simões S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials. 2006 Sep;1(3):217-35. doi: 10.2174/157488706778250050. PMID: 18473975. 5: Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium. Drugs R D. 2007;8(5):321-34. doi: 10.2165/00126839-200708050-00006. PMID: 17767397. 6: Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213. doi: 10.1089/108729002760220798. PMID: 12162702. 7: Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10;24(29):4738-45. doi: 10.1200/JCO.2006.06.0483. Epub 2006 Sep 11. PMID: 16966688. 8: Tarhini AA, Kirkwood JM. Oblimersen in the treatment of metastatic melanoma. Future Oncol. 2007 Jun;3(3):263-71. doi: 10.2217/14796694.3.3.263. PMID: 17547520. 9: Koziner B. Potential therapeutic applications of oblimersen in CLL. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):32-8. PMID: 15651175. 10: Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D; EORTC Genitourinary Tract Cancer Group. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol. 2009 Jul;20(7):1264-9. doi: 10.1093/annonc/mdn784. Epub 2009 Mar 17. PMID: 19297314.